CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
Ligand Pharmaceuticals Announces First Quarter Results
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
Ligand Pharmaceuticals and The Rockefeller University Enter Settlement Agreement and Mutual Release
Ligand Earns $1 Million Milestone Payment on Progress of Drug Candidate for Alzheimer's Disease
Ligand Enters into Screening Agreement with Trevena
Ligand to Present at BIO CEO and Investor Conference on February 9
Ligand Announces Phase IIb Results With DARA
Ligand to Hold Fourth Quarter Results Conference Call on February 12
Ligand Announces Board of Directors Changes
Ligand Completes Pharmacopeia Acquisition
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA(R)
